Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Inflammation in renal insufficiency

Csaba P Kovesdy, MD, FASN
Joel D Kopple, MD
Kamyar Kalantar-Zadeh, MD, MPH, PhD
Section Editor
Jeffrey S Berns, MD
Deputy Editor
Alice M Sheridan, MD


Recurrent or chronic inflammatory processes are common in individuals with chronic renal disease (CKD) and especially end-stage renal disease (ESRD). This is due to many underlying factors, including the uremic milieu, elevated levels of circulating proinflammatory cytokines, oxidative stress, carbonyl stress, protein-energy wasting (PEW), enhanced incidence of infections (especially dialysis access related), and others. Although the definition of inflammation is unclear in this setting, CKD-associated chronic inflammation, as assessed by increased C-reactive protein (CRP) levels above 5 mg/L over at least three months, has been reported in 30 to 60 percent of North American and European dialysis patients, with dialysis patients in Asian countries possibly having a lower prevalence [1-7].

The acute-phase response is a major pathophysiologic phenomenon that accompanies inflammation. With this reaction, normal homeostatic mechanisms are replaced by new set points that presumably contribute to defensive or adaptive capabilities.

Acute-phase proteins are defined as those proteins whose plasma concentrations increase (positive acute-phase proteins), such as CRP, or decrease (negative acute-phase proteins), such as albumin, during inflammatory states. Measurement of the levels of these proteins is frequently utilized to define the presence and/or degree of inflammation in a given patient. A number of inflammatory markers have been studied in patients with CKD (table 1). (See "Acute phase reactants".)

Despite its name, the "acute"-phase response can persist over months to years and become chronic. In such states of chronic inflammation, positive acute-phase proteins including CRP (normal range <1 mg/L) may be slightly but persistently increased, which can predispose to an increased risk of atherosclerotic cardiovascular disease (CVD; CRP 1 to 3 mg/L) [8]. However, in many CKD patients, especially in maintenance dialysis patients, serum CRP levels are persistently between 5 and 50 mg/L, although they may fluctuate widely [8]. During acute and fulminant infections, such as acute osteomyelitis, serum CRP is usually above 50 mg/dL (table 2).

Among patients with CKD, the presence of an inflammatory state may also be closely related to accelerated atherogenesis, protein-energy malnutrition (PEM, also referred to as PEW), and anemia [9-11]:

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Oct 2017. | This topic last updated: Sep 25, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2000; 35:469.
  2. Owen WF, Lowrie EG. C-reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int 1998; 54:627.
  3. Zimmermann J, Herrlinger S, Pruy A, et al. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55:648.
  4. Zoccali C, Benedetto FA, Mallamaci F, et al. Inflammation is associated with carotid atherosclerosis in dialysis patients. Creed Investigators. Cardiovascular Risk Extended Evaluation in Dialysis Patients. J Hypertens 2000; 18:1207.
  5. Iseki K, Tozawa M, Yoshi S, Fukiyama K. Serum C-reactive protein (CRP) and risk of death in chronic dialysis patients. Nephrol Dial Transplant 1999; 14:1956.
  6. Noh H, Lee SW, Kang SW, et al. Serum C-reactive protein: a predictor of mortality in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1998; 18:387.
  7. Kalantar-Zadeh K. Recent advances in understanding the malnutrition-inflammation-cachexia syndrome in chronic kidney disease patients: What is next? Semin Dial 2005; 18:365.
  8. Kalantar-Zadeh K. Inflammatory marker mania in chronic kidney disease: pentraxins at the crossroad of universal soldiers of inflammation. Clin J Am Soc Nephrol 2007; 2:872.
  9. Qureshi AR, Alvestrand A, Divino-Filho JC, et al. Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients. J Am Soc Nephrol 2002; 13 Suppl 1:S28.
  10. Kaysen GA, Dubin JA, Müller HG, et al. Relationships among inflammation nutrition and physiologic mechanisms establishing albumin levels in hemodialysis patients. Kidney Int 2002; 61:2240.
  11. Kalantar-Zadeh K, Kopple JD. Relative contributions of nutrition and inflammation to clinical outcome in dialysis patients. Am J Kidney Dis 2001; 38:1343.
  12. Bemelmans MH, Gouma DJ, Buurman WA. Influence of nephrectomy on tumor necrosis factor clearance in a murine model. J Immunol 1993; 150:2007.
  13. Poole S, Bird TA, Selkirk S, et al. Fate of injected interleukin 1 in rats: sequestration and degradation in the kidney. Cytokine 1990; 2:416.
  14. Panichi V, Migliori M, De Pietro S, et al. C reactive protein in patients with chronic renal diseases. Ren Fail 2001; 23:551.
  15. Stenvinkel P, Heimbürger O, Wang T, et al. High serum hyaluronan indicates poor survival in renal replacement therapy. Am J Kidney Dis 1999; 34:1083.
  16. Guessous I, Ponte B, Marques-Vidal P, et al. Clinical and biological determinants of kidney outcomes in a population-based cohort study. Kidney Blood Press Res 2014; 39:74.
  17. Chung SH, Heimbürger O, Stenvinkel P, et al. Association between inflammation and changes in residual renal function and peritoneal transport rate during the first year of dialysis. Nephrol Dial Transplant 2001; 16:2240.
  18. Pecoits-Filho R, Heimbürger O, Bárány P, et al. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis 2003; 41:1212.
  19. Hasper D, Hummel M, Kleber FX, et al. Systemic inflammation in patients with heart failure. Eur Heart J 1998; 19:761.
  20. Sato Y, Takatsu Y, Kataoka K, et al. Serial circulating concentrations of C-reactive protein, interleukin (IL)-4, and IL-6 in patients with acute left heart decompensation. Clin Cardiol 1999; 22:811.
  21. Sharma R, Bolger AP, Li W, et al. Elevated circulating levels of inflammatory cytokines and bacterial endotoxin in adults with congenital heart disease. Am J Cardiol 2003; 92:188.
  22. Shi K, Wang F, Jiang H, et al. Gut bacterial translocation may aggravate microinflammation in hemodialysis patients. Dig Dis Sci 2014; 59:2109.
  23. Locatelli F, Canaud B, Eckardt KU, et al. The importance of diabetic nephropathy in current nephrological practice. Nephrol Dial Transplant 2003; 18:1716.
  24. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002; 62:1524.
  25. Spittle MA, Hoenich NA, Handelman GJ, et al. Oxidative stress and inflammation in hemodialysis patients. Am J Kidney Dis 2001; 38:1408.
  26. Mezzano D, Pais EO, Aranda E, et al. Inflammation, not hyperhomocysteinemia, is related to oxidative stress and hemostatic and endothelial dysfunction in uremia. Kidney Int 2001; 60:1844.
  27. Stenvinkel P, Holmberg I, Heimbürger O, Diczfalusy U. A study of plasmalogen as an index of oxidative stress in patients with chronic renal failure. Evidence of increased oxidative stress in malnourished patients. Nephrol Dial Transplant 1998; 13:2594.
  28. Miyata T, Ueda Y, Horie K, et al. Renal catabolism of advanced glycation end products: the fate of pentosidine. Kidney Int 1998; 53:416.
  29. Suliman ME, Heimbürger O, Bárány P, et al. Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patients starting on dialysis therapy. J Am Soc Nephrol 2003; 14:1614.
  30. Kalantar-Zadeh K, Kopple JD, Deepak S, et al. Food intake characteristics of hemodialysis patients as obtained by food frequency questionnaire. J Ren Nutr 2002; 12:17.
  31. Langlois M, Duprez D, Delanghe J, et al. Serum vitamin C concentration is low in peripheral arterial disease and is associated with inflammation and severity of atherosclerosis. Circulation 2001; 103:1863.
  32. Deicher R, Ziai F, Bieglmayer C, et al. Low total vitamin C plasma level is a risk factor for cardiovascular morbidity and mortality in hemodialysis patients. J Am Soc Nephrol 2005; 16:1811.
  33. Keane WF, Collins AJ. Influence of co-morbidity on mortality and morbidity in patients treated with hemodialysis. Am J Kidney Dis 1994; 24:1010.
  34. Kshirsagar AV, Moss KL, Elter JR, et al. Periodontal disease is associated with renal insufficiency in the Atherosclerosis Risk In Communities (ARIC) study. Am J Kidney Dis 2005; 45:650.
  35. Kaysen GA. C-reactive protein: a story half told. Semin Dial 2000; 13:143.
  36. Sarnak MJ, Jaber BL. Mortality caused by sepsis in patients with end-stage renal disease compared with the general population. Kidney Int 2000; 58:1758.
  37. Pecoits-Filho R, Stenvinkel P, Marchlewska A, et al. A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. Kidney Int Suppl 2003; :S172.
  38. Chen LP, Chiang CK, Chan CP, et al. Does periodontitis reflect inflammation and malnutrition status in hemodialysis patients? Am J Kidney Dis 2006; 47:815.
  39. Craig RG, Kotanko P, Kamer AR, Levin NW. Periodontal diseases--a modifiable source of systemic inflammation for the end-stage renal disease patient on haemodialysis therapy? Nephrol Dial Transplant 2007; 22:312.
  40. Niedzielska I, Chudek J, Kowol I, et al. The odontogenic-related microinflammation in patients with chronic kidney disease. Ren Fail 2014; 36:883.
  41. Lau WL, Kalantar-Zadeh K, Vaziri ND. The Gut as a Source of Inflammation in Chronic Kidney Disease. Nephron 2015; 130:92.
  42. Sumida K, Molnar MZ, Potukuchi PK, et al. Constipation and Incident CKD. J Am Soc Nephrol 2017; 28:1248.
  43. Schindler R, Boenisch O, Fischer C, Frei U. Effect of the hemodialysis membrane on the inflammatory reaction in vivo. Clin Nephrol 2000; 53:452.
  44. Memoli B, Minutolo R, Bisesti V, et al. Changes of serum albumin and C-reactive protein are related to changes of interleukin-6 release by peripheral blood mononuclear cells in hemodialysis patients treated with different membranes. Am J Kidney Dis 2002; 39:266.
  45. Ayus JC, Sheikh-Hamad D. Silent infection in clotted hemodialysis access grafts. J Am Soc Nephrol 1998; 9:1314.
  46. Cappelli G, Tetta C, Canaud B. Is biofilm a cause of silent chronic inflammation in haemodialysis patients? A fascinating working hypothesis. Nephrol Dial Transplant 2005; 20:266.
  47. Dukkipati R, Molnar MZ, Park J, et al. Association of vascular access type with inflammatory marker levels in maintenance hemodialysis patients. Semin Dial 2014; 27:415.
  48. Hung A, Pupim L, Yu C, et al. Determinants of C-reactive protein in chronic hemodialysis patients: relevance of dialysis catheter utilization. Hemodial Int 2008; 12:236.
  49. Banerjee T, Kim SJ, Astor B, et al. Vascular access type, inflammatory markers, and mortality in incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) Study. Am J Kidney Dis 2014; 64:954.
  50. Sabry AA, Elshafey EM, Alsaran K, et al. The level of C-reactive protein in chronic hemodialysis patients: a comparative study between patients with noninfected catheters and arteriovenous fistula in two large Gulf hemodialysis centers. Hemodial Int 2014; 18:674.
  51. Pecoits-Filho R, Stenvinkel P, Wang AY, et al. Chronic inflammation in peritoneal dialysis: the search for the holy grail? Perit Dial Int 2004; 24:327.
  52. Avram MM, Fein PA, Rafiz MA, et al. Malnutrition and inflammation as predictors of mortality in peritoneal dialysis patients. Kidney Int 2006; 70(Suppl 104):S4.
  53. Yeun JY, Kaysen GA. Acute phase proteins and peritoneal dialysate albumin loss are the main determinants of serum albumin in peritoneal dialysis patients. Am J Kidney Dis 1997; 30:923.
  54. Palomo-Piñón S, Mora-Villalpando CJ, Del Carmen Prado-Uribe M, et al. Inflammation and myocardial damage markers influence loss of residual renal function in peritoneal dialysis patients. Arch Med Res 2014; 45:484.
  55. López-Gómez JM, Pérez-Flores I, Jofré R, et al. Presence of a failed kidney transplant in patients who are on hemodialysis is associated with chronic inflammatory state and erythropoietin resistance. J Am Soc Nephrol 2004; 15:2494.
  56. Akagun T, Caliskan Y, Yazici H, et al. Elevated resistin levels are associated with inflammation in hemodialysis patients with failed renal allografts. Int J Artif Organs 2014; 37:358.
  57. Kimmel PL, Phillips TM, Simmens SJ, et al. Immunologic function and survival in hemodialysis patients. Kidney Int 1998; 54:236.
  58. Streetz KL, Wüstefeld T, Klein C, et al. Mediators of inflammation and acute phase response in the liver. Cell Mol Biol (Noisy-le-grand) 2001; 47:661.
  59. Suffredini AF, Fantuzzi G, Badolato R, et al. New insights into the biology of the acute phase response. J Clin Immunol 1999; 19:203.
  60. Kalantar-Zadeh K, Kleiner M, Dunne E, et al. Total iron-binding capacity-estimated transferrin correlates with the nutritional subjective global assessment in hemodialysis patients. Am J Kidney Dis 1998; 31:263.
  61. Kaysen GA, Dubin JA, Müller HG, et al. The acute-phase response varies with time and predicts serum albumin levels in hemodialysis patients. The HEMO Study Group. Kidney Int 2000; 58:346.
  62. Stenvinkel P, Barany P, Heimbürger O, et al. Mortality, malnutrition, and atherosclerosis in ESRD: what is the role of interleukin-6? Kidney Int Suppl 2002; :103.
  63. Ketteler M, Bongartz P, Westenfeld R, et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003; 361:827.
  64. Panichi V, Maggiore U, Taccola D, et al. Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in haemodialysis patients. Nephrol Dial Transplant 2004; 19:1154.
  65. Kalantar-Zadeh K, Brennan ML, Hazen SL. Serum myeloperoxidase and mortality in maintenance hemodialysis patients. Am J Kidney Dis 2006; 48:59.
  66. Tong M, Carrero JJ, Qureshi AR, et al. Plasma pentraxin 3 in patients with chronic kidney disease: associations with renal function, protein-energy wasting, cardiovascular disease, and mortality. Clin J Am Soc Nephrol 2007; 2:889.
  67. Muntinghe FL, Verduijn M, Zuurman MW, et al. CCR5 deletion protects against inflammation-associated mortality in dialysis patients. J Am Soc Nephrol 2009; 20:1641.
  68. Ducloux D, Bresson-Vautrin C, Kribs M, et al. C-reactive protein and cardiovascular disease in peritoneal dialysis patients. Kidney Int 2002; 62:1417.
  69. Pecoits-Filho R, Bárány P, Lindholm B, et al. Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant 2002; 17:1684.
  70. Wang AY, Woo J, Lam CW, et al. Is a single time point C-reactive protein predictive of outcome in peritoneal dialysis patients? J Am Soc Nephrol 2003; 14:1871.
  71. Kalantar-Zadeh K, Kopple JD, Humphreys MH, Block G. Comparing outcome predictability of markers of malnutrition-inflammation complex syndrome in haemodialysis patients. Nephrol Dial Transplant 2004; 19:1507.
  72. Wang AY, Wang M, Woo J, et al. Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients. J Am Soc Nephrol 2004; 15:2186.
  73. Rao M, Guo D, Perianayagam MC, et al. Plasma interleukin-6 predicts cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2005; 45:324.
  74. Pecoits-Filho R, Lindholm B, Axelsson J, Stenvinkel P. Update on interleukin-6 and its role in chronic renal failure. Nephrol Dial Transplant 2003; 18:1042.
  75. Rambod M, Kovesdy CP, Kalantar-Zadeh K. Combined high serum ferritin and low iron saturation in hemodialysis patients: the role of inflammation. Clin J Am Soc Nephrol 2008; 3:1691.
  76. Kalantar-Zadeh K, Regidor DL, McAllister CJ, et al. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 2005; 16:3070.
  77. Fouque D, Kalantar-Zadeh K, Kopple J, et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int 2008; 73:391.
  78. Kopple JD. Nutritional status as a predictor of morbidity and mortality in maintenance dialysis patients. ASAIO J 1997; 43:246.
  79. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003; 63:793.
  80. Kalantar-Zadeh K, Abbott KC, Kronenberg F, et al. Epidemiology of dialysis patients and heart failure patients. Semin Nephrol 2006; 26:118.
  81. Liu Y, Coresh J, Eustace JA, et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 2004; 291:451.
  82. Flores EA, Bistrian BR, Pomposelli JJ, et al. Infusion of tumor necrosis factor/cachectin promotes muscle catabolism in the rat. A synergistic effect with interleukin 1. J Clin Invest 1989; 83:1614.
  83. Kaizu Y, Kimura M, Yoneyama T, et al. Interleukin-6 may mediate malnutrition in chronic hemodialysis patients. Am J Kidney Dis 1998; 31:93.
  84. Kopple JD, Greene T, Chumlea WC, et al. Relationship between nutritional status and the glomerular filtration rate: results from the MDRD study. Kidney Int 2000; 57:1688.
  85. Kaysen GA, Chertow GM, Adhikarla R, et al. Inflammation and dietary protein intake exert competing effects on serum albumin and creatinine in hemodialysis patients. Kidney Int 2001; 60:333.
  86. Kaysen GA, Dubin JA, Müller HG, et al. Inflammation and reduced albumin synthesis associated with stable decline in serum albumin in hemodialysis patients. Kidney Int 2004; 65:1408.
  87. Bologa RM, Levine DM, Parker TS, et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 1998; 32:107.
  88. Kalantar-Zadeh K, Kopple JD, Block G, Humphreys MH. A malnutrition-inflammation score is correlated with morbidity and mortality in maintenance hemodialysis patients. Am J Kidney Dis 2001; 38:1251.
  89. Kalantar-Zadeh K, Ikizler TA, Block G, et al. Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences. Am J Kidney Dis 2003; 42:864.
  90. Stenvinkel P, Heimbürger O, Lindholm B, et al. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol Dial Transplant 2000; 15:953.
  91. Molnar MZ, Carrero JJ, Mucsi I, et al. Comparison of the malnutrition-inflammation score in chronic kidney disease patients and kidney transplant recipients. Int Urol Nephrol 2015; 47:1025.
  92. Pupim LB, Caglar K, Hakim RM, et al. Uremic malnutrition is a predictor of death independent of inflammatory status. Kidney Int 2004; 66:2054.
  93. Kaysen GA, Stevenson FT, Depner TA. Determinants of albumin concentration in hemodialysis patients. Am J Kidney Dis 1997; 29:658.
  94. Ginn HE, Frost A, Lacy WW. Nitrogen balance in hemodialysis patients. Am J Clin Nutr 1968; 21:385.
  95. Leon JB, Majerle AD, Soinski JA, et al. Can a nutrition intervention improve albumin levels among hemodialysis patients? A pilot study. J Ren Nutr 2001; 11:9.
  96. Leon JB, Albert JM, Gilchrist G, et al. Improving albumin levels among hemodialysis patients: a community-based randomized controlled trial. Am J Kidney Dis 2006; 48:28.
  97. Hulsewé KW, van Acker BA, von Meyenfeldt MF, Soeters PB. Nutritional depletion and dietary manipulation: effects on the immune response. World J Surg 1999; 23:536.
  98. De Simone C, Famularo G, Tzantzoglou S, et al. Carnitine depletion in peripheral blood mononuclear cells from patients with AIDS: effect of oral L-carnitine. AIDS 1994; 8:655.
  99. Rauchhaus M, Coats AJ, Anker SD. The endotoxin-lipoprotein hypothesis. Lancet 2000; 356:930.
  100. deFilippi C, Wasserman S, Rosanio S, et al. Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. JAMA 2003; 290:353.
  101. Stenvinkel P, Heimbürger O, Jogestrand T. Elevated interleukin-6 predicts progressive carotid artery atherosclerosis in dialysis patients: association with Chlamydia pneumoniae seropositivity. Am J Kidney Dis 2002; 39:274.
  102. Sarnak MJ, Coronado BE, Greene T, et al. Cardiovascular disease risk factors in chronic renal insufficiency. Clin Nephrol 2002; 57:327.
  103. Chauveau P, Chadefaux B, Coudé M, et al. Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int Suppl 1993; 41:S72.
  104. Oberg BP, McMenamin E, Lucas FL, et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 2004; 65:1009.
  105. Descamps-Latscha B, Witko-Sarsat V, Nguyen-Khoa T, et al. Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients. Am J Kidney Dis 2005; 45:39.
  106. Kovesdy CP, George SM, Anderson JE, Kalantar-Zadeh K. Outcome predictability of biomarkers of protein-energy wasting and inflammation in moderate and advanced chronic kidney disease. Am J Clin Nutr 2009; 90:407.
  107. Gupta J, Dominic EA, Fink JC, et al. Association between Inflammation and Cardiac Geometry in Chronic Kidney Disease: Findings from the CRIC Study. PLoS One 2015; 10:e0124772.
  108. Kovesdy CP, Kalantar-Zadeh K. Do genes allow inflammation to kill or not to kill? J Am Soc Nephrol 2009; 20:1429.
  109. Muntinghe FL, Verduijn M, Zuurman MW, et al. CCR5 deletion protects against inflammation-associated mortality in dialysis patients. J Am Soc Nephrol 2009; 20:1641.
  110. Kalantar-Zadeh K, Kopple JD, Block G, Humphreys MH. Association among SF36 quality of life measures and nutrition, hospitalization, and mortality in hemodialysis. J Am Soc Nephrol 2001; 12:2797.
  111. Kalantar-Zadeh K, McAllister CJ, Lehn RS, et al. Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am J Kidney Dis 2003; 42:761.
  112. Kalantar-Zadeh K, Don BR, Rodriguez RA, Humphreys MH. Serum ferritin is a marker of morbidity and mortality in hemodialysis patients. Am J Kidney Dis 2001; 37:564.
  113. Gunnell J, Yeun JY, Depner TA, Kaysen GA. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 1999; 33:63.
  114. Beddhu S, Pappas LM, Ramkumar N, Samore MH. Malnutrition and atherosclerosis in dialysis patients. J Am Soc Nephrol 2004; 15:733.
  115. Stenvinkel P, Heimbürger O, Lindholm B. Wasting, but not malnutrition, predicts cardiovascular mortality in end-stage renal disease. Nephrol Dial Transplant 2004; 19:2181.
  116. K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005; 45:S1.
  117. Guarnieri G, Biolo G, Zanetti M, Barazzoni R. Chronic systemic inflammation in uremia: potential therapeutic approaches. Semin Nephrol 2004; 24:441.
  118. Kovesdy CP, Kalantar-Zadeh K. Novel targets and new potential: developments in the treatment of inflammation in chronic kidney disease. Expert Opin Investig Drugs 2008; 17:451.
  119. Vernaglione L, Cristofano C, Muscogiuri P, Chimienti S. Does atorvastatin influence serum C-reactive protein levels in patients on long-term hemodialysis? Am J Kidney Dis 2004; 43:471.
  120. Seliger SL, Weiss NS, Gillen DL, et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 2002; 61:297.
  121. Kumar S, Raftery M, Yaqoob M, Fan SL. Anti-inflammatory effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors (statins) in peritoneal dialysis patients. Perit Dial Int 2007; 27:283.
  122. Deng J, Wu Q, Liao Y, et al. Effect of statins on chronic inflammation and nutrition status in renal dialysis patients: a systematic review and meta-analysis. Nephrology (Carlton) 2012; 17:545.
  123. Chang JW, Yang WS, Min WK, et al. Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. Am J Kidney Dis 2002; 39:1213.
  124. Wanner C, Krane V, März W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353:238.
  125. Fellström BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360:1395.
  126. Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int Suppl 2003; :S207.
  127. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377:2181.
  128. Stenvinkel P, Andersson P, Wang T, et al. Do ACE-inhibitors suppress tumour necrosis factor-alpha production in advanced chronic renal failure? J Intern Med 1999; 246:503.
  129. Agarwal R. Proinflammatory effects of oxidative stress in chronic kidney disease: role of additional angiotensin II blockade. Am J Physiol Renal Physiol 2003; 284:F863.
  130. Boaz M, Smetana S, Weinstein T, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000; 356:1213.
  131. Yang SK, Xiao L, Xu B, et al. Effects of vitamin E-coated dialyzer on oxidative stress and inflammation status in hemodialysis patients: a systematic review and meta-analysis. Ren Fail 2014; 36:722.
  132. Lines SW, Carter AM, Dunn EJ, et al. A randomized controlled trial evaluating the erythropoiesis stimulating agent sparing potential of a vitamin E-bonded polysulfone dialysis membrane. Nephrol Dial Transplant 2014; 29:649.
  133. Yang CC, Hsu SP, Wu MS, et al. Effects of vitamin C infusion and vitamin E-coated membrane on hemodialysis-induced oxidative stress. Kidney Int 2006; 69:706.
  134. Tepel M, van der Giet M, Statz M, et al. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation 2003; 107:992.
  135. Saddadi F, Alatab S, Pasha F, et al. The effect of treatment with N-acetylcysteine on the serum levels of C-reactive protein and interleukin-6 in patients on hemodialysis. Saudi J Kidney Dis Transpl 2014; 25:66.
  136. Stockler-Pinto MB, Mafra D, Moraes C, et al. Brazil nut (Bertholletia excelsa, H.B.K.) improves oxidative stress and inflammation biomarkers in hemodialysis patients. Biol Trace Elem Res 2014; 158:105.
  137. Jun M, Venkataraman V, Razavian M, et al. Antioxidants for chronic kidney disease. Cochrane Database Syst Rev 2012; 10:CD008176.
  138. Ferramosca E, Burke S, Chasan-Taber S, et al. Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. Am Heart J 2005; 149:820.
  139. Yamada K, Fujimoto S, Tokura T, et al. Effect of sevelamer on dyslipidemia and chronic inflammation in maintenance hemodialysis patients. Ren Fail 2005; 27:361.
  140. Vlassara H, Uribarri J, Cai W, et al. Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease. Clin J Am Soc Nephrol 2012; 7:934.
  141. Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005; 68:1815.
  142. Tyrrell DJ, Horne AP, Holme KR, et al. Heparin in inflammation: potential therapeutic applications beyond anticoagulation. Adv Pharmacol 1999; 46:151.
  143. Lever R, Hoult JR, Page CP. The effects of heparin and related molecules upon the adhesion of human polymorphonuclear leucocytes to vascular endothelium in vitro. Br J Pharmacol 2000; 129:533.
  144. Bossola M, Muscaritoli M, Tazza L, et al. Malnutrition in hemodialysis patients: what therapy? Am J Kidney Dis 2005; 46:371.
  145. Lambert CP, Sullivan DH, Evans WJ. Effects of testosterone replacement and/or resistance training on interleukin-6, tumor necrosis factor alpha, and leptin in elderly men ingesting megestrol acetate: a randomized controlled trial. J Gerontol A Biol Sci Med Sci 2003; 58:165.
  146. Mantovani G, Macciò A, Lai P, et al. Cytokine involvement in cancer anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate on cytokine downregulation and improvement of clinical symptoms. Crit Rev Oncog 1998; 9:99.
  147. Mantovani G. Does megestrol acetate down-regulate interleukin-6 in patients? Support Care Cancer 2002; 10:566.
  148. Yeh SS, Wu SY, Levine DM, et al. The correlation of cytokine levels with body weight after megestrol acetate treatment in geriatric patients. J Gerontol A Biol Sci Med Sci 2001; 56:M48.
  149. Boccanfuso JA, Hutton M, McAllister B. The effects of megestrol acetate on nutritional parameters in a dialysis population. J Ren Nutr 2000; 10:36.
  150. Burrowes JD, Bluestone PA, Wang J, Pierson RN Jr. The effects of moderate doses of megestrol acetate on nutritional status and body composition in a hemodialysis patient. J Ren Nutr 1999; 9:89.
  151. Rammohan M, Kalantar-Zadeh K, Liang A, Ghossein C. Megestrol acetate in a moderate dose for the treatment of malnutrition-inflammation complex in maintenance dialysis patients. J Ren Nutr 2005; 15:345.
  152. Gołębiewska JE, Lichodziejewska-Niemierko M, Aleksandrowicz-Wrona E, et al. Influence of megestrol acetate on nutrition, inflammation and quality of life in dialysis patients. Int Urol Nephrol 2012; 44:1211.
  153. Pergola PE, Raskin P, Toto RD, et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 2011; 365:327.
  154. Noori N, Dukkipati R, Kovesdy CP, et al. Dietary omega-3 fatty acid, ratio of omega-6 to omega-3 intake, inflammation, and survival in long-term hemodialysis patients. Am J Kidney Dis 2011; 58:248.
  155. Gharekhani A, Khatami MR, Dashti-Khavidaki S, et al. The effect of omega-3 fatty acids on depressive symptoms and inflammatory markers in maintenance hemodialysis patients: a randomized, placebo-controlled clinical trial. Eur J Clin Pharmacol 2014; 70:655.
  156. Guebre-Egziabher F, Debard C, Drai J, et al. Differential dose effect of fish oil on inflammation and adipose tissue gene expression in chronic kidney disease patients. Nutrition 2013; 29:730.
  157. Deike E, Bowden RG, Moreillon JJ, et al. The effects of fish oil supplementation on markers of inflammation in chronic kidney disease patients. J Ren Nutr 2012; 22:572.
  158. Kovesdy CP, Kalantar-Zadeh K. Vitamin D receptor activation and survival in chronic kidney disease. Kidney Int 2008; 73:1355.
  159. Donate-Correa J, Domínguez-Pimentel V, Méndez-Pérez ML, et al. Selective vitamin D receptor activation as anti-inflammatory target in chronic kidney disease. Mediators Inflamm 2014; 2014:670475.
  160. Alvarez JA, Zughaier SM, Law J, et al. Effects of high-dose cholecalciferol on serum markers of inflammation and immunity in patients with early chronic kidney disease. Eur J Clin Nutr 2013; 67:264.
  161. Miskulin DC, Majchrzak K, Tighiouart H, et al. Ergocalciferol Supplementation in Hemodialysis Patients With Vitamin D Deficiency: A Randomized Clinical Trial. J Am Soc Nephrol 2016; 27:1801.
  162. Chen Y, Abbate M, Tang L, et al. L-Carnitine supplementation for adults with end-stage kidney disease requiring maintenance hemodialysis: a systematic review and meta-analysis. Am J Clin Nutr 2014; 99:408.
  163. Don BR, Kim K, Li J, et al. The effect of etanercept on suppression of the systemic inflammatory response in chronic hemodialysis patients. Clin Nephrol 2010; 73:431.
  164. Identifier: NCT 00293202 www.clinicaltrials.gov (Accessed on June 02, 2008).
  165. Kiely PD, Gillespie KM, Oliveira DB. Oxpentifylline inhibits tumor necrosis factor-alpha mRNA transcription and protects against arthritis in mercuric chloride-treated brown Norway rats. Eur J Immunol 1995; 25:2899.
  166. Rattanasompattikul M, Molnar MZ, Lee ML, et al. Anti-Inflammatory and Anti-Oxidative Nutrition in Hypoalbuminemic Dialysis Patients (AIONID) study: results of the pilot-feasibility, double-blind, randomized, placebo-controlled trial. J Cachexia Sarcopenia Muscle 2013; 4:247.
  167. Antunes SA, Vilela RQ, Vaz JD, Canziani ME. Pentoxifylline does not alter the concentration of hepcidin in chronic kidney disease patients undergoing hemodialysis. Int J Artif Organs 2014; 37:521.
  168. Sabounjian L, Graham P, Wu L, et al. A First-in-Patient, Multicenter, Double-Blind, 2-Arm, Placebo-Controlled, Randomized Safety and Tolerability Study of a Novel Oral Drug Candidate, CTP-499, in Chronic Kidney Disease. Clin Pharmacol Drug Dev 2016; 5:314.
  169. Braman V, Graham P, Cheng C, et al. A Randomized Phase I Evaluation of CTP-499, a Novel Deuterium-Containing Drug Candidate for Diabetic Nephropathy. Clin Pharmacol Drug Dev 2013; 2:53.
  170. Yang BB, Baughman S, Sullivan JT. Pharmacokinetics of anakinra in subjects with different levels of renal function. Clin Pharmacol Ther 2003; 74:85.
  171. Hung AM, Ellis CD, Shintani A, et al. IL-1β receptor antagonist reduces inflammation in hemodialysis patients. J Am Soc Nephrol 2011; 22:437.
  172. Identifier: NCT 00897715. www.clinicaltrials.gov (Accessed on April 22, 2013).
  173. Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 2005; 8:140.
  174. Cambridge G, Leandro MJ, Edwards JC, et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 2003; 48:2146.
  175. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350:2572.
  176. Cambridge G, Leandro MJ, Teodorescu M, et al. B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum 2006; 54:3612.
  177. Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52:262.
  178. Keogh KA, Ytterberg SR, Fervenza FC, et al. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006; 173:180.
  179. Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum 2006; 54:2970.
  180. Kamar N, Faguer S, Esposito L, et al. Treatment of focal segmental glomerular sclerosis with rituximab: 2 case reports. Clin Nephrol 2007; 67:250.
  181. Milovanova SIu, Lopatkina TN, Kozlovskaia LV, Krasnova TN. [Monoclonal antibodies to B-lymphocytes (rituximab) in the treatment of HCV-associated severe cryoglobulinemic glomerulonephritis]. Ter Arkh 2007; 79:69.
  182. Ponticelli C. New therapies for lupus nephritis. Clin J Am Soc Nephrol 2006; 1:863.
  183. Ruggenenti P, Chiurchiu C, Abbate M, et al. Rituximab for idiopathic membranous nephropathy: who can benefit? Clin J Am Soc Nephrol 2006; 1:738.
  184. Smith RJ, Alexander J, Barlow PN, et al. New approaches to the treatment of dense deposit disease. J Am Soc Nephrol 2007; 18:2447.
  185. de Zeeuw D, Bekker P, Henkel E, et al. The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial. Lancet Diabetes Endocrinol 2015; 3:687.
  186. Menne J, Eulberg D, Beyer D, et al. C-C motif-ligand 2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients with albuminuria. Nephrol Dial Transplant 2017; 32:307.
  187. Perez-Gomez MV, Sanchez-Niño MD, Sanz AB, et al. Targeting inflammation in diabetic kidney disease: early clinical trials. Expert Opin Investig Drugs 2016; 25:1045.
  188. Bloembergen WE, Hakim RM, Stannard DC, et al. Relationship of dialysis membrane and cause-specific mortality. Am J Kidney Dis 1999; 33:1.
  189. Maduell F, Moreso F, Pons M, et al. High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. J Am Soc Nephrol 2013; 24:487.
  190. Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS Jr. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem 2001; 276:22382.
  191. Castaneda C, Gordon PL, Parker RC, et al. Resistance training to reduce the malnutrition-inflammation complex syndrome of chronic kidney disease. Am J Kidney Dis 2004; 43:607.